Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Longeveron Inc. (LGVN : NSDQ)

• Company Description    Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI. Number of Employees: 26

• Price / Volume Information    Yesterday's Closing Price: $0.51 Daily Weekly Monthly 20 Day Moving Average: 334,761 shares Shares Outstanding: 21.33 (millions) Market Capitalization: $10.79 (millions) Beta: 0.21 52 Week High: $2.24 52 Week Low: $0.49 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.02% -19.89% 12 Week -42.82% -43.74% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1951 NW 7TH AVENUE SUITE 520 - MIAMI,FL 33136 USA ph: 305-909-0840 fax: - investorrelations@longeveron.com https://longeveron.com

• General Corporate Information    Officers Mohamed Wa'el Ahmed Hashad - Chief Executive Officer Lisa A. Locklear - Executive Vice President and Chief Financial Offic Joshua M. Hare - Director Rock Soffer - Director Richard Kender - Director Peer Information Longeveron Inc. (CORR.) Longeveron Inc. (RSPI) Longeveron Inc. (CGXP) Longeveron Inc. (BGEN) Longeveron Inc. (GTBP) Longeveron Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 54303L203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/27/26 Share - Related Items Shares Outstanding: 21.33 Most Recent Split Date: 3.00 (0.10:1) Beta: 0.21 Market Capitalization: $10.79 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/27/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.07 Price/Cash Flow: - Price / Sales: 7.51 EPS Growth vs. Year Ago Period: -14.71% vs. Previous Quarter: -18.18% Sales Growth vs. Year Ago Period: -82.28% vs. Previous Quarter: -56.65% ROE 12/31/25 - - 09/30/25 - -138.44 06/30/25 - -95.91 ROA 12/31/25 - - 09/30/25 - -108.46 06/30/25 - -79.69 Current Ratio 12/31/25 - - 09/30/25 - 2.09 06/30/25 - 3.43 Quick Ratio 12/31/25 - - 09/30/25 - 2.09 06/30/25 - 3.43 Operating Margin 12/31/25 - - 09/30/25 - -1,485.25 06/30/25 - -894.40 Net Margin 12/31/25 - - 09/30/25 - -1,485.25 06/30/25 - -894.40 Pre-Tax Margin 12/31/25 - - 09/30/25 - -1,485.25 06/30/25 - -894.40 Book Value 12/31/25 - - 09/30/25 - 0.47 06/30/25 - 0.83 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©